Wells Fargo & Company Ultragenyx Pharmaceutical Inc. Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 33,257 shares of RARE stock, worth $1.49 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

33,257

Previous 28,859 15.24%

Holding current value

$1.49 Million

Previous $1.19 Million 55.73%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$40.21 - $59.36 $176,843 - $261,065	4,398 Added 15.24%	33,257 $1.85 Million
Q2 2024 Aug 13, 2024	SELL	$37.42 - $51.61 $95,383 - $131,553	-2,549 Reduced 8.12%	28,859 $1.19 Million
Q1 2024 May 10, 2024	SELL	$43.02 - $53.69 $445,170 - $555,584	-10,348 Reduced 24.78%	31,408 $1.47 Million
Q4 2023 Feb 09, 2024	SELL	$31.73 - $49.19 $609,755 - $945,284	-19,217 Reduced 31.52%	41,756 $2 Million
Q3 2023 Nov 13, 2023	BUY	$34.92 - $46.66 $677,203 - $904,877	19,393 Added 46.64%	60,973 $2.17 Million
Q2 2023 Aug 15, 2023	SELL	$37.35 - $52.15 $2,763 - $3,859	-74 Reduced 0.18%	41,580 $1.92 Million
Q1 2023 May 12, 2023	BUY	$36.99 - $48.71 $1.15 Million - $1.52 Million	31,124 Added 295.57%	41,654 $1.67 Million
Q4 2022 Feb 13, 2023	BUY	$33.72 - $46.33 $83,693 - $114,991	2,482 Added 30.84%	10,530 $487,000
Q3 2022 Nov 14, 2022	SELL	$39.96 - $66.14 $131,748 - $218,063	-3,297 Reduced 29.06%	8,048 $333,000
Q2 2022 Aug 12, 2022	BUY	$45.8 - $85.4 $277,593 - $517,609	6,061 Added 114.7%	11,345 $677,000
Q1 2022 May 16, 2022	BUY	$62.2 - $84.4 $120,170 - $163,060	1,932 Added 57.64%	5,284 $383,000
Q4 2021 Feb 14, 2022	SELL	$73.71 - $87.86 $161,867 - $192,940	-2,196 Reduced 39.58%	3,352 $282,000
Q3 2021 Nov 15, 2021	SELL	$77.92 - $102.4 $4.04 Million - $5.31 Million	-51,885 Reduced 90.34%	5,548 $500,000
Q2 2021 Aug 16, 2021	SELL	$92.19 - $115.71 $1.51 Million - $1.9 Million	-16,433 Reduced 22.25%	57,433 $5.48 Million
Q1 2021 May 13, 2021	SELL	$106.9 - $167.73 $1.15 Million - $1.81 Million	-10,777 Reduced 12.73%	73,866 $8.41 Million
Q4 2020 Feb 09, 2021	BUY	$84.4 - $177.39 $3.66 Million - $7.7 Million	43,404 Added 105.25%	84,643 $11.7 Million
Q3 2020 Nov 05, 2020	SELL	$72.98 - $90.0 $1.3 Million - $1.6 Million	-17,775 Reduced 30.12%	41,239 $3.39 Million
Q2 2020 Aug 13, 2020	BUY	$46.91 - $78.22 $1.13 Million - $1.88 Million	24,075 Added 68.91%	59,014 $4.62 Million
Q1 2020 May 14, 2020	BUY	$33.8 - $62.9 $1.18 Million - $2.2 Million	34,939 New	34,939 $1.55 Million

Others Institutions Holding RARE

# of Institutions

326

Shares Held

85.7M

Call Options Held

520K

Put Options Held

406K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.15B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Ultragenyx Pharmaceutical Inc. Transaction History